ONL1204 Ophthalmic Solution

DRUG3 trials

Sponsors

ONL Therapeutics Inc., ONL Therapeutics

Conditions

Atrophic Age-related Macular Degeneration (AMD)Geographic AtrophyRhegmatogenous Retinal Detachment - Macula Off

Phase 1

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

CompletedNCT04744662

ONL TherapeuticsGeographic Atrophy

Start: 2021-07-08End: 2024-02-29Updated: 2024-11-19

Phase 2

A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal Detachment

CompletedNCT05730218

ONL TherapeuticsRhegmatogenous Retinal Detachment - Macula Off

Start: 2023-04-04End: 2024-02-21Updated: 2024-02-29

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

Not yet recruitingCTIS2024-513174-22-00

ONL Therapeutics Inc.Atrophic Age-related Macular Degeneration (AMD)

Target: 182Updated: 2025-08-11